Please Wait.....
Report
Global Dengue Treatment Market
Market Report I 2024-06-01 I 360 Pages I Data Bridge Market Research
Global dengue treatment market is expected to reach USD 2,121.43 million by 2031, from USD 878.54 million in 2023 growing at the CAGR of 11.6% in the forecast period of 2024 to 2031.
Market Segmentation:
Global Dengue Treatment Market, By Strains (DENV-2, DENV-3, DENV-1, DENV-4, and Others), Type (Vaccines and Acetaminophen), Severity (Mild to Moderate Dengue and Severe Dengue), Route of Administration (Parenteral and Oral), Mode of Purchase (Prescription and Over-the-Counter (OTC)), Gender (Male and Female), Age (Adult, Pediatric, and Geriatric), End User (Hospital, Specialty Clinics, Home Healthcare, and Others), Distribution Channel (Retail Pharmacies, Hospital Pharmacies, and Online Pharmacies), By Countries (U.S., Canada, Mexico, Germany, U.K., Italy, France, Spain, Russia, Switzerland, Turkey, Belgium, Netherlands, Rest of Europe, Japan, China, South Korea, India, Singapore, Thailand, Indonesia, Malaysia, Philippines, Australia, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Egypt, Saudi Arabia, U.A.E., Israel, and Rest of Middle East and Africa) - Industry Trends and Forecast to 2031
Overview of Global Dengue treatment Market Dynamics:
Driver
- Rising dengue incidence rate result in the demand for effective treatment
Restrain
- Delay in the approval process of vaccines
Opportunity
- Growing number of pipeline vaccines for dengue treatment
Market Players:
The key market players operating in the global dengue treatment market are listed below:
- Sanofi
- Takeda Pharmaceutical Company Limited
- Viatris Inc.
- Johnson & Johnson
- GSK plc.
- Perrigo Company PLC
- Baxter
- Fresenius Kabi USA
- Pfizer
- Hikma Pharmaceuticals PLC
- Sun Pharmaceutical Industries Ltd
- Teva Pharmaceuticals USA, Inc.
- Aurobindo Pharma
1 INTRODUCTION 41
1.1 OBJECTIVES OF THE STUDY 41
1.2 MARKET DEFINITION 41
1.3 OVERVIEW OF THE GLOBAL DENGUE TREATMENT MARKET 41
1.4 CURRENCY AND PRICING 43
1.5 LIMITATIONS 43
1.6 MARKETS COVERED 44
2 MARKET SEGMENTATION 47
2.1 MARKETS COVERED 47
2.2 GEOGRAPHICAL SCOPE 48
2.3 YEARS CONSIDERED FOR THE STUDY 49
2.4 DBMR TRIPOD DATA VALIDATION MODEL 50
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 53
2.6 MULTIVARIATE MODELLING 54
2.7 MARKET APPLICATION COVERAGE GRID 55
2.8 PRODUCT LIFELINE CURVE 56
2.9 DBMR MARKET POSITION GRID 57
2.10 VENDOR SHARE ANALYSIS 58
2.11 SECONDARY SOURCES 59
2.12 ASSUMPTIONS 59
3 EXECUTIVE SUMMARY 60
4 PREMIUM INSIGHTS 63
4.1 PESTEL ANALYSIS 66
4.2 PORTER'S FIVE FORCES 67
5 GLOBAL DENGUE TREATMENT MARKET: REGULATIONS 68
5.1 U.S. REGULATORY SCENARIO FOR DENGUE TREATMENT 69
5.2 EUROPE REGULATORY SCENARIO FOR DENGUE TREATMENT 69
5.3 DEVELOPING COUNTRIES REGULATORY FRAMEWORK 70
5.4 LEGISLATION FOR CONTROL OF DENGUE IN SINGAPORE 70
5.5 DVCRN DEVELOPING VACCINE REGULATORS NETWORK 71
?
6 MARKET OVERVIEW 72
6.1 DRIVERS 74
6.1.1 RISING DENGUE INCIDENCE RATE RESULT IN THE DEMAND FOR EFFECTIVE TREATMENT 74
6.1.2 RISING WAVE OF DENGUE VACCINE LAUNCHES 74
6.1.3 GOVERNMENT INITIATIVES AND VACCINATION PROGRAMS 75
6.1.4 GROWTH OF MEDICAL INSURANCE IN EMERGING COUNTRIES 76
6.2 RESTRAINTS 77
6.2.1 DELAY IN THE APPROVAL PROCESS OF VACCINES 77
6.2.2 LACK OF AWARENESS AND HEALTHCARE INFRASTRUCTURE FOR TREATMENT OF DENGUE 78
6.2.3 DIFFICULTY IN THE DETECTION ASSAY FOR DENGUE 79
6.3 OPPORTUNITIES 80
6.3.1 STRATEGIC COLLABORATION WITHIN THE PHARMACEUTICAL INDUSTRY FUELS THE MARKET 80
6.3.2 GROWING NUMBER OF PIPELINE VACCINES FOR DENGUE TREATMENT 80
6.3.3 RISING R&D INVESTMENT AND ACTIVITIES 81
6.4 CHALLENGES 82
6.4.1 HEALTHCARE SERVICES ARE LIMITEDLY ACCESSIBLE IN RURAL AREAS 82
6.4.2 HIGH COSTS OF TREATMENT RESTRICT THE FEASIBILITY OF COST-EFFECTIVE SOLUTIONS 82
7 GLOBAL DENGUE TREATMENT MARKET, BY STRAINS 84
7.1 OVERVIEW 85
7.2 DENV-2 88
7.3 DENV-3 88
7.4 DENV-1 89
7.5 DENV-4 89
7.6 OTHERS 90
8 GLOBAL DENGUE TREATMENT MARKET, BY TYPE 91
8.1 OVERVIEW 92
8.2 VACCINES 95
8.2.1 DENGVAXIA (CYD-TDV) 96
8.2.2 QDENGA 96
8.3 ACETAMINOPHEN 96
8.3.1 PARENTERAL 97
8.3.2 ORAL 97
8.3.3 OTHER 97
?
9 GLOBAL DENGUE TREATMENT MARKET, BY SEVERITY 98
9.1 OVERVIEW 99
9.2 MILD TO MODERATE DENGUE 102
9.3 SEVERE DENGUE 102
10 GLOBAL DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 103
10.1 OVERVIEW 104
10.2 PARENTERAL 107
10.2.1 SUB-CUTANEOUS 107
10.2.2 INTRAVENOUS 107
10.3 ORAL 108
10.3.1 TABLET 108
10.3.2 CAPSULES 108
10.3.3 OTHERS 108
11 GLOBAL DENGUE TREATMENT MARKET, BY MODE OF PURCHASE 109
11.1 OVERVIEW 110
11.2 PRESCRIPTION 113
11.3 OVER-THE-COUNTER (OTC) 113
12 GLOBAL DENGUE TREATMENT MARKET, BY GENDER 114
12.1 OVERVIEW 115
12.2 MALE 118
12.3 FEMALE 118
13 GLOBAL DENGUE TREATMENT MARKET, BY AGE 119
13.1 OVERVIEW 120
13.2 ADULT 123
13.3 PEDIATRIC 123
13.4 GERIATRIC 124
14 GLOBAL DENGUE TREATMENT MARKET, BY END USER 125
14.1 OVERVIEW 126
14.2 HOSPITAL 129
14.3 SPECIALTY CLINICS 129
14.4 HOME HEALTHCARE 130
14.5 OTHERS 130
15 GLOBAL DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL 131
15.1 OVERVIEW 132
15.2 RETAIL PHARMACIES 135
15.3 HOSPITAL PHARMACIES 135
15.4 ONLINE PHARMACIES 136
16 GLOBAL DENGUE TREATMENT MARKET, BY REGION 137
16.1 OVERVIEW 138
16.2 ASIA-PACIFIC 142
16.2.1 INDIA 148
16.2.2 CHINA 153
16.2.3 JAPAN 158
16.2.4 INDONESIA 163
16.2.5 MALAYSIA 168
16.2.6 THAILAND 173
16.2.7 AUSTRALIA 178
16.2.8 SOUTH KOREA 183
16.2.9 SINGAPORE 188
16.2.10 PHILIPPINES 193
16.2.11 REST OF ASIA-PACIFIC 198
16.3 SOUTH AMERICA 199
16.3.1 BRAZIL 204
16.3.2 ARGENTINA 209
16.3.3 REST OF SOUTH AMERICA 214
16.4 NORTH AMERICA 215
16.4.1 MEXICO 220
16.4.2 U.S. 225
16.4.3 CANADA 230
16.5 EUROPE 235
16.5.1 FRANCE 241
16.5.2 GERMANY 246
16.5.3 SPAIN 251
16.5.4 U.K. 256
16.5.5 BELGIUM 261
16.5.6 ITALY 266
16.5.7 NETHERLANDS 271
16.5.8 RUSSIA 276
16.5.9 SWITZERLAND 281
16.5.10 TURKEY 286
16.5.11 REST OF EUROPE 290
?
16.6 MIDDLE EAST AND AFRICA 291
16.6.1 EGYPT 297
16.6.2 SAUDI ARABIA 302
16.6.3 SOUTH AFRICA 307
16.6.4 U.A.E 312
16.6.5 ISRAEL 317
16.6.6 REST OF MIDDLE EAST AND AFRICA 322
17 GLOBAL DENGUE TREATMENT MARKET: COMPANY LANDSCAPE 323
17.1 COMPANY SHARE ANALYSIS: GLOBAL 323
17.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 324
17.3 COMPANY SHARE ANALYSIS: EUROPE 325
17.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 326
17.5 COMPANY SHARE ANALYSIS: SOUTH AMERICA 327
18 SWOT ANALYSIS 328
19 COMPANY PROFILE 329
19.1 SANOFI 329
19.1.1 COMPANY SNAPSHOT 329
19.1.2 REVENUE ANALYSIS 329
19.1.3 COMPANY SHARE ANALYSIS 330
19.1.4 PRODUCT PORTFOLIO 330
19.1.5 RECENT DEVELOPMENTS 330
19.2 TAKEDA PHARMACEUTICAL COMPANY LIMITED 331
19.2.1 COMPANY SNAPSHOT 331
19.2.2 REVENUE ANALYSIS 331
19.2.3 COMPANY SHARE ANALYSIS 332
19.2.4 PRODUCT PORTFOLIO 332
19.2.5 RECENT DEVELOPMENTS 332
19.3 VIATRIS INC. 334
19.3.1 COMPANY SNAPSHOT 334
19.3.2 REVENUE ANALYSIS 335
19.3.3 COMPANY SHARE ANALYSIS 335
19.3.4 PRODUCT PORTFOLIO 335
19.3.5 RECENT DEVELOPMENTS 336
19.4 JOHNSON & JOHNSON SERVICES, INC. 337
19.4.1 COMPANY SNAPSHOT 337
19.4.2 REVENUE ANALYSIS 337
19.4.3 COMPANY SHARE ANALYSIS 338
19.4.4 PRODUCT PORTFOLIO 338
19.4.5 RECENT DEVELOPMENT 338
19.5 GSK PLC. 340
19.5.1 COMPANY SNAPSHOT 340
19.5.2 REVENUE ANALYSIS 340
19.5.3 COMPANY SHARE ANALYSIS 341
19.5.4 PRODUCT PORTFOLIO 341
19.5.5 RECENT DEVELOPMENTS 341
19.6 AUROBINDO PHARMA 342
19.6.1 COMPANY SNAPSHOT 342
19.6.2 REVENUE ANALYSIS 342
19.6.3 PRODUCT PORTFOLIO 343
19.7 BAXTER 344
19.7.1 COMPANY SNAPSHOT 344
19.7.2 REVENUE ANALYSIS 344
19.7.3 PRODUCT PORTFOLIO 345
19.8 FRESENIUS KABI USA 346
19.8.1 COMPANY SNAPSHOT 346
19.8.2 PRODUCT PORTFOLIO 346
19.8.3 RECENT DEVELOPMENTS 346
19.9 HIKMA PHARMACEUTICALS 347
19.9.1 COMPANY SNAPSHOT 347
19.9.2 REVENUE ANALYSIS 347
19.9.3 PRODUCT PORTFOLIO 348
19.9.4 RECENT DEVELOPMENT 348
19.10 PERRIGO COMPANY PLC 349
19.10.1 COMPANY SNAPSHOT 349
19.10.2 REVENUE ANALYSIS 349
19.10.3 PRODUCT PORTFOLIO 350
19.10.4 RECENT DEVELOPMENT 350
19.11 PFIZER INC. 351
19.11.1 COMPANY SNAPSHOT 351
19.11.2 REVENUE ANALYSIS 351
19.11.3 PRODUCT PORTFOLIO 352
19.11.4 RECENT DEVELOPMENTS 352
19.12 SUN PHARMACEUTICAL INDUSTRIES LTD 353
19.12.1 COMPANY SNAPSHOT 353
19.12.2 REVENUE ANALYSIS 354
19.12.3 PRODUCT PORTFOLIO 354
19.12.4 RECENT DEVELOPMENT 354
?
19.13 TEVA PHARMACEUTICALS USA, INC. 355
19.13.1 COMPANY SNAPSHOT 355
19.13.2 REVENUE ANALYSIS 355
19.13.3 PRODUCT PORTFOLIO 356
19.13.4 RECENT DEVELOPMENT 356
20 QUESTIONNAIRE 357
21 RELATED REPORTS 360
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security